CBD Suppositories Showed Promise for Chronic Pelvic Pain in Men

Single-arm, open-label pilot trial. 16 men (ages 24–49) with CP/CPPS (NIH-CPSI >10, pain subscore ≥4). Self-administered rectal CANNEFF suppositories (100 mg CBD + 6.6 mg hyaluronic acid) nightly for 30 days. Outcomes: NIH-CPSI total score, International Prostate Symptom Score, International Index of Erectile Function. Safety and tolerability assessed.

CP/CPPS is a common condition with limited treatment options and significant quality-of-life impact. This is one of the first clinical trials of CBD specifically for pelvic pain, and the rectal delivery route addresses CBD's well-known bioavailability problem. While the open-label design means results need confirmation in controlled trials, the 81% response rate is encouraging for a condition where many patients find little relief from standard treatments.

This trial takes CBD research in an unusual direction — treating pelvic pain via rectal delivery. It connects to the broader CBD mechanisms review (RTHC-00258) showing anti-inflammatory effects in the gut/pelvic region, and to the bioavailability research (RTHC-00246) that documented challenges with oral CBD. The combination with hyaluronic acid (a tissue-protective agent) represents a multimodal approach that's different from typical cannabinoid studies using single compounds.

Very small sample (N=16) with no placebo control group — the placebo response in chronic pain conditions is typically 20–40%, so some improvement would be expected without active treatment. Single-arm open-label design cannot establish efficacy. The combined CBD/hyaluronic acid formulation makes it impossible to determine which component is responsible for effects. 30-day treatment period is short for a chronic condition.